Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Expands Functionality of its Leading Solution for Quantitative Digital Pathology

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
Definiens Tissue Studio now supports the detection of spot-like signals from in situ hybridization assays.

Definiens® has announced that Definiens Tissue Studio® 3.5 now supports the automated analysis of in situ hybridization assays, including SISH, CISH, FISH and dual-ISH.

The unique combination of flexibility and ease-of-use that characterizes Definiens Tissue Studio® significantly facilitates the detection of spot-like signals originating from gene probes (or any other stain with spot-like appearance) on a cell-by-cell basis.

Definiens Tissue Studio® supports the detection of gene probe signals in both brightfield and immunofluorescene imaging.

The novel functionality complements the robust detection of regions of interest and the comprehensive quantification of cellular parameters and biomarker expression profiles.

Definiens Tissue Studio® can be used to analyze images from any solid tissue with any stain, acquired by any scanner or microscope, and in any common file format.

With these technological advances, pathologists and researchers can adapt preconfigured solutions to their specific assays with just a few clicks in no more than 30 minutes.

Straightforward workflow, intuitive configuration, as well as flexibility and robustness, have established Definiens Tissue Studio as the leading image analysis solution for quantitative digital pathology.

Definiens Tissue Studio opens new dimensions in quantification by significantly reducing study times in translational research, preclinical safety, tissue-based biomarker development and clinical trials around the world.

The new version includes a range of improvements that make it easier to use and more powerful than ever.

“Definiens has developed significant experience in the analysis of in situ hybridization assays in recent years,” said Thomas Heydler, CEO of Definiens.

Heydler continued, “In Definiens Tissue Studio® 3.5, we now make this available to our customers in a very easy-to-use workflow that supports virtually any type of 2D ISH assay. This further strengthens Definiens Tissue Studio’s position as the most comprehensive software package for quantitative digital pathology.”

With just a single configuration, Definiens Tissue Studio® automates the detection of regions of interest and has the capacity to distinguish individual cells and subcellular structures even in heterogeneous tissues samples.

The software provides quantitative readouts on morphological characteristics and molecular expression profiles of nuclear, cytoplasmic and membrane biomarkers.

In addition, Definiens Tissue Studio® supports robust detection of vessels for automated angiogenesis assays as well as extensive multiplexing for the quantification of numerous parameters from the same tissue sample in immunofluorescence assays.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!